Synchron, Inc.

Synchron, Inc. is a medical device technology company founded in 2016 by Thomas Oxley, with its headquarters located in New York, New York. The company focuses on developing endovascular brain-computer interface solutions for patients with motor impairments. It acquired SmartStent, an earlier venture by Oxley, and obtained an equity stake in Acquandas to support component manufacturing for its devices.

Business/Product Breakdown

Synchron, Inc. offers the Stentrode brain-computer interface system, an implantable device deployed through blood vessels in a minimally invasive endovascular procedure to capture and translate brain signals into digital commands without requiring open-brain surgery. The platform includes electrode arrays on a stent-like structure for neural signal detection, integration with external processors for real-time interpretation, and compatibility with devices such as Apple products via Bluetooth protocols for hands-free control of iPads, iPhones, and Vision Pro using Switch Control. Additional features encompass cognitive AI for decoding thought patterns, on-device neural processing enhancements, and support for applications in assistive technology, enabling users with conditions like paralysis to perform tasks such as navigation, app usage, and communication through thought alone.

a company that develops brain implants that turn thoughts into text, raises $200MM Series D from Double Point Ventures.